Structure based inhibitor design targeting glycogen phosphorylase B. Virtual screening, synthesis, biochemical and biological assessment of novel N-acyl-β-d-glucopyranosylamines.

Glycogen phosphorylase (GP) is a validated target for the development of new type 2 diabetes treatments. Exploiting the Zinc docking database, we report the in silico screening of 1888 N-acyl-β-d-glucopyranosylamines putative GP inhibitors differing only in their R groups. CombiGlide and GOLD docking programs with different scoring functions were employed with the best performing methods combined in a 'consensus scoring' approach to ranking of ligand binding affinities for the active site. Six selected candidates from the screening were then synthesized and their inhibitory potency was assessed both in vitro and ex vivo. Their inhibition constants' values, in vitro, ranged from 5 to 377μM while two of them were effective at causing inactivation of GP in rat hepatocytes at low μM concentrations. The crystal structures of GP in complex with the inhibitors were defined and provided the structural basis for their inhibitory potency and data for further structure based design of more potent inhibitors.

[1]  N. Oikonomakos,et al.  Advances in glycogen phosphorylase inhibitor design. , 2008, Current opinion in investigational drugs.

[2]  L. Johnson,et al.  Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. , 1991, Biochemistry.

[3]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[4]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[5]  S. Zographos,et al.  New inhibitors of glycogen phosphorylase as potential antidiabetic agents. , 2008, Current medicinal chemistry.

[6]  B. Tóth,et al.  Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies. , 2002, European journal of biochemistry.

[7]  A. Souers,et al.  Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production. , 2003, Current medicinal chemistry.

[8]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[9]  R. Clark,et al.  Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.

[10]  S. Zographos,et al.  The binding of C5-alkynyl and alkylfurano[2,3-d]pyrimidine glucopyranonucleosides to glycogen phosphorylase b: synthesis, biochemical and biological assessment. , 2012, European journal of medicinal chemistry.

[11]  L. Johnson,et al.  Crystallographic binding studies on the allosteric inhibitor glucose-6-phosphate to T state glycogen phosphorylase b. , 1993, Journal of molecular biology.

[12]  S. Zographos,et al.  1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies. , 2010, Bioorganic & medicinal chemistry.

[13]  Miklos Feher,et al.  Consensus scoring for protein-ligand interactions. , 2006, Drug discovery today.

[14]  Tom Fawcett,et al.  An introduction to ROC analysis , 2006, Pattern Recognit. Lett..

[15]  H. Waterbeemd,et al.  Fromin vivotoin vitro/in silicoADME: progress and challenges , 2005 .

[16]  L. Agius.  Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors. , 2010, Mini reviews in medicinal chemistry.

[17]  V. L. Rath,et al.  Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. , 2000, Chemistry & biology.

[18]  D. Schmoll,et al.  The role of glucose 6‐phosphate in mediating the effects of glucokinase overexpression on hepatic glucose metabolism , 2006, The FEBS journal.

[19]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[20]  S. Zographos,et al.  The binding of β-d-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors. , 2010, Bioorganic & medicinal chemistry.

[21]  L. Somsák,et al.  Synthesis of N-(β-D-glucopyranosyl)- and N-(2-acetamido-2-deoxy-β-D-glucopyranosyl) amides as inhibitors of glycogen phosphorylase , 2004 .

[22]  D. Leonidas,et al.  Computation as a tool for glycogen phosphorylase inhibitor design. , 2010, Mini reviews in medicinal chemistry.

[23]  Pierre Baldi,et al.  A CROC stronger than ROC: measuring, visualizing and optimizing early retrieval , 2010, Bioinform..

[24]  D. Leonidas,et al.  Biochemical and biological assessment of the inhibitory potency of extracts from vinification byproducts of Vitis vinifera extracts against glycogen phosphorylase. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[25]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[26]  D. Leonidas,et al.  Natural products and their derivatives as inhibitors of glycogen phosphorylase: potential treatment for type 2 diabetes , 2014, Phytochemistry Reviews.

[27]  L. Johnson,et al.  The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. , 1997, Structure.

[28]  Robert P. Sheridan.  Alternative Global Goodness Metrics and Sensitivity Analysis: Heuristics to Check the Robustness of Conclusions from Studies Comparing Virtual Screening Methods , 2008, J. Chem. Inf. Model..

[29]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[30]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[31]  G. Pahlke,et al.  Natural flavonoids are potent inhibitors of glycogen phosphorylase. , 2006, Molecular nutrition & food research.

[32]  L. Agius.  New hepatic targets for glycaemic control in diabetes. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[33]  N. Oikonomakos,et al.  Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site. , 2006, Bioorganic & medicinal chemistry.

[34]  L. Somsák.  Glucose derived inhibitors of glycogen phosphorylase , 2011 .

[35]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[36]  T N Thompson,et al.  Early ADME in support of drug discovery: the role of metabolic stability studies. , 2000, Current drug metabolism.

[37]  R. Roy,et al.  Phase Transfer Catalysis as a General and Stereoselective Entry into Glycosyl Azides from Glycosyl Halides , 1992 .

[38]  J. Kieswich,et al.  A Novel Mechanism for Regulating Hepatic Glycogen Synthesis Involving Serotonin and Cyclin-Dependent Kinase-5 , 2011, Diabetes.

[39]  J. Guinovart,et al.  Hepatic Glycogen Synthesis Is Highly Sensitive to Phosphorylase Activity , 2001, The Journal of Biological Chemistry.

[40]  S. Zographos,et al.  The σ‐Hole Phenomenon of Halogen Atoms Forms the Structural Basis of the Strong Inhibitory Potency of C5 Halogen Substituted Glucopyranosyl Nucleosides towards Glycogen Phosphorylase b , 2012, ChemMedChem.

[41]  L. Agius,et al.  Glucose 6-phosphate causes translocation of phosphorylase in hepatocytes and inactivates the enzyme synergistically with glucose. , 2004, The Biochemical journal.

[42]  L. Agius,et al.  Glucose 6-phosphate regulates hepatic glycogenolysis through inactivation of phosphorylase. , 2003, Diabetes.

[43]  M. Murcko,et al.  Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. , 1999, Journal of medicinal chemistry.

[44]  A. Souers,et al.  Prospects for pharmacologic inhibition of hepatic glucose production. , 2003, Current medicinal chemistry.

[45]  N. Oikonomakos.  Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. , 2002, Current protein & peptide science.

[46]  Randy J. Read,et al.  Evolving methods for macromolecular crystallography : the structural path to the understanding of the mechanism of action of CBRN agents , 2007 .

[47]  L. Somsák,et al.  Synthesis of heterocyclic N-(β-D-glucopyranosyl)carboxamides for inhibition of glycogen phosphorylase. , 2012, Carbohydrate research.

[48]  B. Tóth,et al.  Synthesis of and a comparative study on the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of d-gluco- and d-xylopyranosylidene-spiro-(thio)hydantoins and N-(d-glucopyranosyl) amides. , 2001, Journal of medicinal chemistry.

[49]  N. Oikonomakos,et al.  Inhibition of rabbit muscle glycogen phosphorylase by D-gluconohydroximo-1,5-lactone-N-phenylurethane. , 1989, Archives of biochemistry and biophysics.

[50]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[51]  James L. Melville,et al.  Better than Random? The Chemotype Enrichment Problem , 2009, J. Chem. Inf. Model..

[52]  J. Treadway,et al.  Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus , 2001, Expert opinion on investigational drugs.

[53]  S. Zographos,et al.  Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors. , 2009, Bioorganic & medicinal chemistry.